• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Adjuvant Clonidine for Mania
Research Update

Adjuvant Clonidine for Mania

March 8, 2023
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Michael Posternak, MD. Dr. Posternak has no financial relationships with companies related to this material.

REVIEW OF: Ahmadpanah M et al, J Psych Research 2022;146:163–171

STUDY TYPE: Randomized controlled trial

Long ago in the 1980s, clonidine showed promise in an open-label and a small controlled trial of bipolar mania, but those findings were never followed up until now. This antihypertensive has alpha-agonist as well as serotonergic and dopaminergic effects. It is well tolerated and has potential benefits in symptoms that are relevant to mania, including insomnia, anxiety, and irritability. Clonidine is FDA approved in ADHD, and this study tested whether it would also improve cognition during active mania.

Researchers in Iran randomized 70 inpatients with acute mania to receive either adjuvant clonidine or placebo in addition to lithium (dosage range 900–1200 mg/day) over the course of 24 days. Clonidine was started at 0.2 mg/day and titrated toward a maximum of 0.6 mg/day (given as two divided doses in the evening). The primary outcome was improvement in mania as measured by the Young Mania Rating Scale (YMRS). Secondary outcomes were sleep as measured by the Pittsburgh Sleep Quality Index (PSQI) and cognition as measured by the Mini-Mental State Examination (MMSE).

Compared to placebo, those on adjuvant clonidine achieved significantly lower endpoint YMRS scores on day 24 (9.8 vs 13.6) and slept better (PSQI = 4.5 vs 5.9), but no differences were found in cognition as measured by the MMSE. The corresponding effect sizes were large for mania (0.9) and medium for sleep (0.6). Adverse effects were not reported, but typical tolerability issues with clonidine include sedation and hypotension (in this study, the drug was held if the blood pressure dropped below 100/60 mmHg for two consecutive days).

The majority (84%) of patients were male, which may limit the generalizability of the findings. Also, the MMSE is a coarse instrument for measuring cognition, and it is possible that subtle differences in cognition were not elicited by this instrument.

CARLAT TAKE

Consider clonidine augmentation in mania when patients don’t respond to or cannot tolerate conventional option

General Psychiatry
KEYWORDS bipolar bipolar disorder cognition mania mood disorders
Michael Posternak, MD.

Trichotillomania: Diagnosis and Treatment

More from this author
www.thecarlatreport.com
Issue Date: March 8, 2023
SUBSCRIBE NOW
Table Of Contents
Learning Objectives, Complementary Therapies, TCPR, March 2023
Deep Rivers Run Quiet. An Update on Social Anxiety Disorder
Herbal Therapies for Depression
Four Controversial Diagnoses in Psychiatry: Are They Valid?
Adjuvant Clonidine for Mania
CME Post-Test, Complementary Therapies, TCPR, March 2023
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.